19.3 C
Friday, August 19, 2022
HomeBusinessDanish 'meme stock' Orphazyme plunges after drug setback By Reuters

Danish ‘meme stock’ Orphazyme plunges after drug setback By Reuters


Related stories

Advantages of Windows 10 Activator Txt

Computers have made the life of human beings run...

Why do small businesses need professional web design services?

Web design is an essential element of digital marketing–...

Unique Methods of Relaxation That Are Surprisingly Effective

It might not make sense, but everyone knows what...

Morgan Stanley downgrades Elanco to equal weight on profit questions

Morgan Stanley is moving to the sidelines on...

M&N Locksmith Chicago: Locksmith Services – Experience The Difference With Us!

Locksmithing is an age-old industry. People would usually use...

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo


By Stine Jacobsen

(Reuters) -Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate, sending shares in Denmark’s first so-called meme stock tumbling 75% in early trading.

Shares in the biotech company, which is yet to have a drug approved or make money, have been on a roller-coaster recently – like other “meme stocks” influenced by chatter on social media – as investors took positions ahead of the U.S. Food and Drug Administration’s (FDA) decision.

Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.

As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.

“Orphazyme has no money and no substantial projects … Investors have put their money into a completely unrealistic scenario driven by ‘meme tendencies’,” broker Nordnet wrote in a note to clients.

Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.

The company said the FDA in a letter had said additional qualitative and quantitative evidence was needed to show the drug’s effectiveness.

“As representative for Orphazyme’s shareholders and as a shareholder myself, I am extremely disappointed,” deputy board chairman Bo Jesper Hansen said in a statement.

The drugmaker said it would remain in dialogue with the FDA and would continue to seek approval for the treatment in Europe.

($1 = 6.2456 Danish crowns)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Latest stories